Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
June 03, 2024 08:00 ET
|
Cyclacel
CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA AT 2024 ASCO ANNUAL MEETING HIGHLIGHTING ORAL FADRACICLIB’S POTENTIAL AS A PRECISION MEDICINE FOR CANCER
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
May 23, 2024 17:00 ET
|
Evaxion Biotech
EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both...
Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology
April 16, 2024 16:05 ET
|
Kamari Pharma
Late breaking poster presentation includes Phase 1b clinical trial results demonstrating the safety and preliminary efficacy of KM-001, a topical TRPV3 inhibitor, for the treatment of palmoplantar...
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
April 01, 2024 16:01 ET
|
Gritstone bio
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
March 22, 2024 07:00 ET
|
OKYO Pharma LTD
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)
January 30, 2024 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV) Les deux groupes de...
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)
January 30, 2024 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024 07:00 ET
|
OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...